Search results
Showing 91 to 105 of 123 results for nivolumab
In development [GID-TA10745] Expected publication date: 17 July 2024
Awaiting development [GID-TA11048] Expected publication date: TBC
Evidence-based recommendations on pembrolizumab (Keytruda) with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults.
Regorafenib for previously treated metastatic colorectal cancer (TA866)
Evidence-based recommendations on regorafenib (Stivarga) for previously treated metastatic colorectal cancer in adults.
treating lipodystrophy TBC Non-small cell lung cancer (non-squamous) - nivolumab (CDF review TA484) [ID1572] Back to top
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
Discontinued [GID-TA10148]
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) with bevacizumab (Avastin) for treating metastatic colorectal cancer after 2 systemic treatments in adults.
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma (TA666)
Evidence-based recommendations on atezolizumab (Tecentriq) with bevacizumab (Avastin) for treating advanced or unresectable hepatocellular carcinoma in adults who have not had previous systemic treatment.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults.
Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea (TA777)
Evidence-based recommendations on solriamfetol (Sunosi) for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Everolimus for advanced renal cell carcinoma after previous treatment (TA432)
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma after previous treatment.